Polarean Imaging Plc Total Liabilities

Latest as of June 2025: GBX3.19 Million GBX ≈ $387.94 USD

Polarean Imaging Plc total liabilities. Based on the latest financial reports, Polarean Imaging Plc (POLX) has total liabilities worth GBX3.19 Million GBX (≈ $387.94 USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See POLX days of operational coverage to measure how many days the company can operate on defensive assets alone.

Total Liabilities of Polarean Imaging Plc (2014–2024)

Total liabilities of Polarean Imaging Plc from 2014 to 2024. This chart illustrates how Polarean Imaging Plc's total liabilities have evolved over time, based on quarterly financial data.

Polarean Imaging Plc Competitors by Total Liabilities

The table below lists competitors of Polarean Imaging Plc ranked by their total liabilities.

Company Country Total Liabilities
Plaza Centers NV
LSE:PLAZ
UK GBX205.76 Million
Hana Microelectronics Public Company Limited
F:HAA1
Germany €4.68 Billion
Red Rock Resources
LSE:RRR
UK GBX8.60 Million
PTT Global Chemical Public Company Limited
F:GCB
Germany €310.60 Billion
Fantasy Network Ltd
TA:FNTS
Israel ILA755.00K
Bluebird Merchant Ventures Ltd
LSE:BMV
UK GBX4.64 Million
PTT Public Company Limited
F:PTOG
Germany €1.84 Trillion
Mingzhu Logistics Holdings Ltd
NASDAQ:YGMZ
USA $22.99 Million

Liability Composition Analysis (2014–2024)

This chart breaks down Polarean Imaging Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see POLX total assets.

Liquidity & Leverage Metrics

Polarean Imaging Plc Total Liabilities Ratios Explained

Polarean Imaging Plc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 3.56 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.40 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.29 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Polarean Imaging Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Polarean Imaging Plc (2014–2024)

The table below shows the annual total liabilities of Polarean Imaging Plc from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 GBX3.65 Million
≈ $444.06
+41.23%
2023-12-31 GBX2.58 Million
≈ $314.42
-20.05%
2022-12-31 GBX3.23 Million
≈ $393.27
+15.78%
2021-12-31 GBX2.79 Million
≈ $339.66
+30.02%
2020-12-31 GBX2.15 Million
≈ $261.23
-12.37%
2019-12-31 GBX2.45 Million
≈ $298.11
+20.26%
2018-12-31 GBX2.04 Million
≈ $247.87
-39.25%
2017-12-31 GBX3.35 Million
≈ $408.04
+216.31%
2016-12-31 GBX1.06 Million
≈ $129.00
-6.09%
2015-12-31 GBX1.13 Million
≈ $137.37
-17.35%
2014-12-31 GBX1.37 Million
≈ $166.20
--

About Polarean Imaging Plc

LSE:POLX UK Medical Devices
Market Cap
$11.75K
GBX96.56 Million GBX
Market Cap Rank
#31859 Global
#1291 in UK
Share Price
GBX0.08
Change (1 day)
-20.00%
52-Week Range
GBX0.08 - GBX0.22
All Time High
GBX106.50
About

Polarean Imaging plc operates as a drug-device manufacturer and service provider for noble gas hyperpolariser devices in Canada, the United Kingdom, and the United States. The company engages in the research, development, and commercialization of novel imaging solutions with a non-invasive and radiation-free functional imaging platform. It also offers XENOVIEW, a hyperpolarized contrast agent ind… Read more